Bovine viral diarrhea virus (BVDV), a Flaviviridae pestivirus, is arguably one of the most widespread cattle pathogens worldwide. Each of its two genotypes has two biotypes, non-cytopathic (ncp) and cytopathic (cp). Only the ncp biotype of BVDV may establish persistent infection in the fetus when infecting a dam early in gestation, a time point which predates maturity of the adaptive immune system. Such fetuses may develop and be born healthy but remain infected for life. Due to this early initiation of fetal infection and to the expression of interferon antagonistic proteins, persistently infected (PI) animals remain immunotolerant to the infecting viral strain. Although only accounting for some 1% of all animals in regions where BVDV is endemic, PI animals ensure the viral persistence in the host population. These animals may, however, develop the fatal mucosal disease, which is characterized by widespread lesions in the gastrointestinal tract. Cp BVD virus, in addition to the persisting ncp biotype, can be isolated from such animals. The cp viruses are characterized by unrestrained genome replication, and their emergence from the persisting ncp ones is due to mutations that are unique in each virus analyzed. They include recombinations with host cell mRNA, gene translocations and duplications, and point mutations. Cytopathic BVD viruses fail to establish chains of infection and are unable to cause persistent infection. Hence, these viruses illustrate a case of “viral emergence to extinction” – irrelevant for BVDV evolution, but fatal for the PI host.

No abstract

Background Equine parvovirus‐hepatitis (EqPV‐H) research is in its infancy. Information regarding prevalence, geographical distribution, genetic diversity, pathogenesis and risk factors enhances understanding of this potentially fatal infection. Objectives Determining the prevalence of EqPV‐H in Austrian equids. Investigating factors increasing probability of infection, liver‐associated biochemistry parameters, concurrent equine hepacivirus (EqHV) infection and phylogenetic analysis of Austrian EqPV‐H variants. Study design Cross‐sectional study. Methods Sera from 259 horses and 13 donkeys in Austria were analysed for anti‐EqPV‐H VP1‐specific antibodies by luciferase immunoprecipitation system (LIPS) and EqPV‐H DNA by nested polymerase chain reaction (PCR). Associations between infection status, sex and age were described. Glutamate dehydrogenase (GLDH), gamma‐glutamyl transferase (GGT), bile acids and albumin concentrations were compared between horses with active infection and PCR‐negative horses. PCR targeting partial EqPV‐H NS1 was performed and phylogenetic analysis of Austrian EqPV‐H variants was conducted. Complete coding sequences (CDS) of four Austrian variants were determined by next‐generation sequencing (NGS) and compared with published sequences. Results Horses' EqPV‐H seroprevalence was 30.1% and DNA prevalence was 8.9%. One horse was co‐infected with EqHV. Significantly, higher probability of active EqPV‐H infection was identified in 16‐ to 31‐year‐old horses, compared with 1‐ to 8‐year‐old horses (P = 0.002; OR = 8.19; 95% CI = 1.79 to 37.50) and 9‐ to 15‐year‐old horses (P = 0.03; OR = 2.96; 95% CI = 1.08 to 8.17). Liver‐associated plasma parameters were not significantly different between horses with active infection and controls. Austrian EqPV‐H variants revealed high similarity to sequences worldwide. No evidence of EqPV‐H was detected in donkeys. Main limitations Equids’ inclusion depended upon owner consent. There was only one sampling point per animal and the sample of donkeys was small. Conclusions EqPV‐H antibodies and DNA are frequently detected in Austrian horses, without associated hepatitis in horses with active infection. The risk of active EqPV‐H infection increases with increasing age. Phylogenetic evidence supports close relation of EqPV‐H variants globally, including Austrian variants.

No abstract

No abstract